Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Panacea Venture is a life sciences venture fund founded in 2017, emerging from Kleiner Perkins China. The firm operates from multiple locations, including Shanghai, Boston, and Silicon Valley, and focuses on investing in innovative healthcare and life sciences companies. With a portfolio of over 30 companies, Panacea Venture emphasizes early-stage and growth-stage investments, as well as public companies.
The firm has established itself as a key player in the healthcare investment space, leveraging its expertise to support the development of technologies that address unmet medical needs. Notable milestones include its rapid growth since inception and its strategic focus on Asian markets, particularly China, which enhances its investment capabilities.
Panacea Venture invests primarily in early-stage companies that develop breakthrough technologies in the life sciences sector. The firm targets sectors such as therapeutics, small molecules, biologics, alternative modalities, cell and gene therapy, and R&D services. Its investment strategy is characterized by a global focus, with a particular emphasis on Asia, especially China.
Investment stages range from pre-seed to growth equity, allowing Panacea to engage with startups at various points in their development. The firm seeks to identify and support innovations that address significant medical needs, emphasizing the importance of therapeutic advancements and innovative healthcare solutions in its investment thesis.
Panacea Venture's portfolio includes over 30 companies, showcasing a diverse range of innovative healthcare solutions. Notable portfolio companies include:
This diverse portfolio reflects Panacea Venture's commitment to supporting companies that are at the forefront of healthcare innovation.
James Huang: Founder and Managing Partner, with a background in venture capital and life sciences, previously associated with Kleiner Perkins.
Andrew Aherrera: Partner, specializing in healthcare investments and strategic partnerships.
Cheryl Bao: Chief Legal Officer, responsible for legal affairs and compliance within the firm.
Benjamin Chen: Scientific Partner, with expertise in biotechnology and drug development.
Arthur Chen: Partner, focusing on investment strategy and portfolio management.
Michelle Chung: Venture Partner, involved in sourcing and evaluating new investment opportunities.
Delia Ding: Chief Financial Officer, overseeing financial operations and fund management.
Nancy Donahue: Venture Partner, contributing to deal sourcing and due diligence.
Carl Firth: Partner, with a focus on healthcare technology investments and market analysis.
To pitch Panacea Venture, founders should send their proposals via email to info@panaceaventure.com. A comprehensive pitch deck is essential, including details about the business model, technology, market opportunity, and team background.
While there is no specific application form, a well-structured deck that highlights the innovation and potential impact of the startup will increase the chances of a favorable response. Founders should expect a response time of approximately 2-4 weeks after submission.
As of October 2023, Panacea Venture has continued to expand its portfolio, actively investing in innovative healthcare solutions. The firm has maintained a focus on early-stage and growth-stage companies, particularly in the life sciences sector.
Recent investments include notable companies in therapeutics and regenerative medicine, reflecting the firm's commitment to addressing unmet medical needs. However, no specific exits or fund raises have been reported in the latest updates.
What are Panacea Venture's investment criteria?
Panacea Venture focuses on early-stage companies with breakthrough technologies in the life sciences sector. They prioritize innovations that address unmet medical needs across various healthcare sectors.
How can startups apply or pitch to Panacea Venture?
Startups can reach out to Panacea Venture via email at info@panaceaventure.com. A detailed pitch deck outlining the business model, technology, and market opportunity is recommended.
What makes Panacea Venture different from other investors?
Panacea Venture's unique focus on life sciences and its expertise in Asian markets, particularly China, set it apart. The firm leverages its background from Kleiner Perkins China to identify and support innovative healthcare solutions.
What is the geographic scope of Panacea Venture's investments?
The firm has a global investment strategy with a strong emphasis on Asia, especially China. This geographic focus allows them to tap into emerging healthcare innovations in these regions.
What is the typical check size for investments?
While specific check sizes are not disclosed, Panacea Venture invests across various stages, including pre-seed, seed, seed-plus, series A, and growth equity, indicating a flexible approach to funding.
What is Panacea Venture's post-investment involvement like?
Panacea Venture actively supports its portfolio companies through mentorship, operational support, and access to its extensive network in the life sciences sector, enhancing the growth potential of its investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.